Mission
We are committed to providing the best sample for a complete picture of a patient’s cancer
Vision
To make precision medicine a reality by advancing rare cell diagnostics
Values
Innovation, dedication, enthusiasm and compassion
Our Parsortix technology has the potential to deliver profound improvements in clinical and health economic outcomes in the diagnosis and treatment of cancer
The patented Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis
The ability to monitor and analyse CTCs may transform the treatment of MBC, providing patients with personalised cancer care through a non-invasive, repeatable liquid biopsy
Discover more
Onc-ADaPTTM laboratories utilize Parsotix technology in combination with both standardized and custom assays for the analysis of epithelial and mesenchymal CTCs for biopharmaceutical and translational researchers
These assays have the potential to provide clinicians with up-to-date, clinically actionable insight into a patient’s cancer, and may result in improved clinical outcomes for those individuals
A message from
Andrew Newland
